Barclays PLC Boosts Stock Holdings in Exelixis, Inc. $EXEL

Barclays PLC increased its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 11.0% in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor owned 732,686 shares of the biotechnology company’s stock after buying an additional 72,377 shares during the quarter. Barclays PLC owned about 0.27% of Exelixis worth $30,260,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Richardson Financial Services Inc. lifted its position in shares of Exelixis by 95.1% during the 3rd quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 292 shares in the last quarter. Root Financial Partners LLC bought a new stake in Exelixis in the 3rd quarter valued at $28,000. Luminist Capital LLC lifted its position in shares of Exelixis by 2,740.0% in the second quarter. Luminist Capital LLC now owns 710 shares of the biotechnology company’s stock worth $31,000 after buying an additional 685 shares in the last quarter. Abich Financial Wealth Management LLC bought a new position in shares of Exelixis during the 3rd quarter valued at approximately $47,000. Finally, Elevation Point Wealth Partners LLC bought a new position in Exelixis during the second quarter valued at $60,000. 85.27% of the stock is currently owned by hedge funds and other institutional investors.

Exelixis Stock Down 2.5%

Shares of NASDAQ EXEL opened at $41.29 on Wednesday. The company’s 50-day simple moving average is $43.45 and its 200-day simple moving average is $41.64. Exelixis, Inc. has a 52-week low of $32.38 and a 52-week high of $49.62. The firm has a market cap of $10.72 billion, a price-to-earnings ratio of 14.91, a price-to-earnings-growth ratio of 0.95 and a beta of 0.41.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.20. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The firm had revenue of $598.66 million for the quarter, compared to the consensus estimate of $609.17 million. During the same period last year, the firm posted $0.55 earnings per share. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. Equities research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Insider Activity at Exelixis

In other news, CFO Christopher J. Senner sold 34,278 shares of the stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $43.00, for a total value of $1,473,954.00. Following the completion of the transaction, the chief financial officer owned 1,042,579 shares in the company, valued at $44,830,897. This trade represents a 3.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Patrick J. Haley sold 67,814 shares of Exelixis stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $43.52, for a total transaction of $2,951,265.28. Following the transaction, the executive vice president owned 381,908 shares of the company’s stock, valued at approximately $16,620,636.16. The trade was a 15.08% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 362,849 shares of company stock worth $15,917,463 over the last ninety days. 2.85% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

EXEL has been the topic of several analyst reports. Wolfe Research started coverage on shares of Exelixis in a report on Tuesday, November 18th. They set a “peer perform” rating on the stock. Stifel Nicolaus lifted their price objective on Exelixis from $43.00 to $44.00 and gave the company a “hold” rating in a report on Wednesday, February 11th. Zacks Research cut Exelixis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 5th. Barclays lifted their price target on shares of Exelixis from $41.00 to $44.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 4th. Finally, Morgan Stanley upped their price target on shares of Exelixis from $48.00 to $49.00 and gave the company an “equal weight” rating in a research note on Monday, February 2nd. Ten equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Exelixis has a consensus rating of “Hold” and a consensus target price of $46.94.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.